Allos Therapeutics, Inc.

210 articles about Allos Therapeutics, Inc.

• Allos Therapeutics, Inc. To Present At Upcoming Investor Conferences

  8/29/2006

• Allos Therapeutics, Inc. Initiates Pivotal Phase 2 Study Of PDX In Patients With Peripheral T-Cell Lymphoma

  8/29/2006

• Allos Therapeutics, Inc. Reports Second Quarter 2006 Financial Results

  8/7/2006

• Allos Therapeutics, Inc. Receives Special Protocol Assessment For Pivotal Phase 2 Study Of The Company's Novel Antifolate PDX In Patients With Peripheral T-Cell Lymphoma

  8/2/2006

• FDA Grants Orphan Drug Designation To Allos Therapeutics, Inc.'s Novel Antifolate PDX For The Treatment of T-Cell Lymphoma

  7/26/2006

• The Day In Review: Biotech 4.5% Higher In 3 Days

  7/25/2006

• Allos Therapeutics, Inc. Files Shelf Registration Statement

  6/13/2006

• Allos Therapeutics, Inc. To Present At The 2006 Needham & Company Biotechnology Conference

  6/7/2006

• Allos Therapeutics, Inc. Appoints James V. Caruso As Chief Commercial Officer

  6/6/2006

• Allos Therapeutics, Inc.' EFAPROXYN(TM) Found To Reduce Tumor Hypoxia And HIF-1-alpha Expression In Human Breast Cancer Xenografts

  6/5/2006

• Allos Therapeutics, Inc. Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350

  5/26/2006

• Allos Therapeutics, Inc. Reports First Quarter 2006 Financial Results

  5/9/2006

• Interim Analysis Supports Continuation Of Allos Therapeutics, Inc.'s Pivotal Phase 3 Trial

  4/4/2006

• Allos Therapeutics, Inc. Names Chief Executive Offficer

  3/10/2006

• Allos Therapeutics, Inc. Reports 2005 Financial Results

  3/6/2006

• Allos Therapeutics, Inc. To Present At The 2006 SG Cowen & Co., LLC Healthcare Conference

  3/1/2006

• Scheduled Combination Of Allos Therapeutics, Inc.' Pralatrexate Plus Gemcitabine Proves Superior To Methotrexate Plus Cytarabine In Models Of Human Non-Hodgkin's Lymphoma

  2/14/2006

• Allos Therapeutics, Inc. To Present At The 2006 Biotechnology Industry Organization (BIO) CEO & Investor Conference

  2/1/2006

• Allos Therapeutics, Inc. Announces CEO Succession Plans

  1/17/2006

• Allos Therapeutics, Inc. Release: Results Published In Journal Of Clinical Oncology Affirm Survival Benefit Of EFAPROXYN(TM) In Patients With Brain Metastases Originating From Breast Cancer

  1/3/2006